The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of response rate and disease control rate as potential predictors of overall survival in anthracycline-pretreated women receiving first-line chemotherapy for metastatic breast cancer (MBC).
J. Liu
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
K. S. Albain
Consultant or Advisory Role - Lilly
Honoraria - Lilly
Research Funding - Lilly
S. Chan
Research Funding - Lilly
A. D. Seidman
Consultant or Advisory Role - Lilly
Honoraria - Lilly
Research Funding - Lilly
D. Tai
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Y. Wang
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
L. Zhao
Employment or Leadership Position - Lilly
Stock Ownership - Lilly